Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD.
Body Mass Index
Canada
/ epidemiology
Carbon Monoxide
/ analysis
Exercise Tolerance
Female
Humans
Male
Middle Aged
Mortality
Patient Acuity
Predictive Value of Tests
Prognosis
Pulmonary Diffusing Capacity
Pulmonary Disease, Chronic Obstructive
/ diagnosis
Risk Assessment
/ methods
Smoking
/ epidemiology
Spain
/ epidemiology
Spirometry
/ methods
Walk Test
/ methods
COPD
Dlco
clinical
mortality
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
20
01
2021
revised:
01
03
2021
accepted:
12
04
2021
pubmed:
27
4
2021
medline:
7
1
2022
entrez:
26
4
2021
Statut:
ppublish
Résumé
The Global Initiative for Obstructive Lung Disease (GOLD) does not promote diffusing capacity for carbon monoxide (Dlco) values in the evaluation of COPD. In GOLD spirometric stage I COPD patients, the clinical and prognostic impact of a low Dlco has not been explored. Could a Dlco threshold help define an increased risk of death and a different clinical presentation in these patients? GOLD stage I COPD patients (n = 360) were enrolled and followed over 109 ± 50 months. Age, sex, pack-years' history, BMI, dyspnea, lung function measurements, exercise capacity, BODE index, and history of exacerbations were recorded. A cutoff value for Dlco was identified for all-cause mortality and the clinical and physiological characteristics of patients above and below the threshold compared. Cox regression analysis explored the predictive power of that cutoff value for all-cause mortality. A Dlco cutoff value of <60% predicted was associated with all-cause mortality (Dlco ≥ 60%: 9% vs Dlco < 60%: 23%, P = .01). At a same FEV
Sections du résumé
BACKGROUND
The Global Initiative for Obstructive Lung Disease (GOLD) does not promote diffusing capacity for carbon monoxide (Dlco) values in the evaluation of COPD. In GOLD spirometric stage I COPD patients, the clinical and prognostic impact of a low Dlco has not been explored.
RESEARCH QUESTION
Could a Dlco threshold help define an increased risk of death and a different clinical presentation in these patients?
STUDY DESIGN AND METHODS
GOLD stage I COPD patients (n = 360) were enrolled and followed over 109 ± 50 months. Age, sex, pack-years' history, BMI, dyspnea, lung function measurements, exercise capacity, BODE index, and history of exacerbations were recorded. A cutoff value for Dlco was identified for all-cause mortality and the clinical and physiological characteristics of patients above and below the threshold compared. Cox regression analysis explored the predictive power of that cutoff value for all-cause mortality.
RESULTS
A Dlco cutoff value of <60% predicted was associated with all-cause mortality (Dlco ≥ 60%: 9% vs Dlco < 60%: 23%, P = .01). At a same FEV
Identifiants
pubmed: 33901498
pii: S0012-3692(21)00757-1
doi: 10.1016/j.chest.2021.04.033
pmc: PMC8448999
pii:
doi:
Substances chimiques
Carbon Monoxide
7U1EE4V452
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
872-878Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
Références
Lancet. 2007 Sep 1;370(9589):741-50
pubmed: 17765523
Am Rev Respir Dis. 1991 Nov;144(5):1202-18
pubmed: 1952453
Arch Bronconeumol. 2012 Dec;48(12):453-9
pubmed: 22766419
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Eur Respir J. 2017 Sep 11;50(3):
pubmed: 28893868
Chest. 2007 Dec;132(6):1778-85
pubmed: 17925409
Int J Chron Obstruct Pulmon Dis. 2018 Oct 26;13:3549-3561
pubmed: 30464437
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
J Appl Physiol (1985). 2019 Oct 1;127(4):1107-1116
pubmed: 31369329
Respir Med. 2006 Jan;100(1):115-22
pubmed: 15893923
COPD. 2013 Feb;10(1):79-103
pubmed: 23272663
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Eur Respir J. 2005 Oct;26(4):720-35
pubmed: 16204605
Chest. 2002 May;121(5):1434-40
pubmed: 12006425
Eur Respir J. 2013 Sep;42(3):616-25
pubmed: 23349449
Eur Respir J. 2018 Feb 7;51(2):
pubmed: 29437944
Thorax. 2003 May;58(5):388-93
pubmed: 12728157
Chest. 2019 Dec;156(6):1111-1119
pubmed: 31352035
N Engl J Med. 2004 Mar 4;350(10):1005-12
pubmed: 14999112
Arch Bronconeumol. 2017 Mar;53(3):128-149
pubmed: 28274597
Thorax. 2006 Sep;61(9):744-6
pubmed: 16936234
Lancet. 2005 Nov 26;366(9500):1875-81
pubmed: 16310554